Reviewing contemporary patient centered treatment strategies and management approaches for schizophrenia patients: A comprehensive analysis

Bhuvaneshwari V[1], Vignesh sri V[1], Dr.Diana Antony Peter[2], Dr.Lavanya A[2*]

[1]Faculty of pharmacy, Karpagam Academy of Higher Education, Coimbatore.
[2, 2]Assistant professor, Faculty of pharmacy, Karpagam Academy of Higher Education, Coimbatore.*
[2]Email: lavanyalavi221199@gmail.com*

Abstract:

The severe, lifelong condition schizophrenia impairs emotional, behavioral, and cognitive functioning. Many people with schizophrenia continue to be impaired and have several relapses. Physicians should understand how important it is to treat patients with schizophrenia with a patient-centered approach in order to enhance their clinical and functional results. Strategies that might lead to improved results include providing psycho-social therapies, using collaborative decision-making, and streamlining the drug regimen. The study investigated the impact of interventions on person-focused views, quality of life, satisfaction, acceptance, adherence to therapies, treatment planning, and outcomes. Cognitive therapy, psychoeducation, family intervention, social skills training, and active community treatment are the main psycho-social intervention modalities utilised in the treatment of schizophrenia. The health care providers can implement the PCD approach by using some of the most well-known UCD techniques, such as focus groups, surveys, interviews, and participatory design. This article provides a thorough analysis of the state-of-the-art psycho-social therapies for individuals with schizophrenia. Its strengths and drawbacks include the few data on long-term benefits.

Keywords: *Pharm.D professionals, patient counselling, schizophrenia, therapeutic guidelines.*

1. Introduction:

Schizophrenia is a chronic mental disorder affecting brain processing and information use, affecting early brain development and presenting with cognitive, negative, and psychotic symptoms.[1]In the 1800s, Dr. Emil Krapelin was the first to describe schizophrenia. He was the director of the university's psychiatric clinic in Estonia. He first referred to it as dementia Praecox, or early dementia.[2] Psychosis can cause changes in a person's worldview, actions, and ideas. Some individuals experience intermittent symptoms, while others experience persistently worsening symptoms over time.

[3] Cognitive symptoms include problems with focus, memory, and attention. When these symptoms are present, it might be challenging to keep track of appointments, follow a conversation, or pick up new skills. Loss of drive, disinterest in or enjoyment of everyday activities, social retreat, trouble expressing feelings, and other negative symptoms.[4] [6] .Five main psychosocial intervention techniques have been used to treat schizophrenia: family intervention, cognitive therapy (also called cognitive behavioural and cognitive remediation therapy), aggressive community treatment, psychoeducation, and social skills training.[5] The person-centred approach views patients as active participants in meaning development, acknowledging their self-awareness efforts as beneficial rather than detrimental.[7] We outline three modern tools for a person-centered psychopathology: value-based practise, interpretive psychopathology, and modern methods for the meanings-causes controversy.[8] A patient-reported outcome is one that they provide directly, without modification or interpretation by the physician or another third party, on their health, quality of life, or functional status.[9] If the interviewer only notes the patient's response, this can be ascertained through interview.[10] Absolute measurements of these outcomes—like a patient's assessment of the intensity of their depression—may be possible. Patient-reported outcome measures, typically self-completed questionnaires, assess symptom burden, functional status, health-related quality of life, personal care experience, and health-related behaviors like anxiety and depression.[11] [12] Patients may report on several domains related to schizophrenia using multiple patient-reported outcomes. Beyond positive symptoms, symptom control in other clinical domains is necessary to enhance outcomes for individuals with schizophrenia.[13][14] Better results could be achieved by utilizing shared decision-making, streamlining the drug schedule, and providing psychological therapies.[15]

2. Importance of patient centered care:

Patient-centered care strategy involves collaboration, team decision-making, and emotional, social, and economical needs, addressing physical, emotional, social, and economical needs, aiming to improve health outcomes. It was long believed that patient-centered care is always preferable to other approaches and is also more well-liked by patients. Patients have families, feelings, concerns, questions, and opinions. When treating patients, a patient-centered approach emphasizes collaboration and addressing the patient as a whole, a person with specific concerns.[16]

2a. Defining patient-centered care

Patient-centered care, also known as person-centered care, ensures respect, dignity, and a voice in healthcare decisions, promoting a person's entitlement to healthcare.[16] [17] Patient-centered care involves active family participation, respecting individual preferences, and allowing patients to make health-related decisions .[18] When you receive patient-centered care from medical providers and services, you are placed at the "center" of your treatment by:

- Being considerate, civil, and respectful towards you.
- Managing your treatment and exchanging information with different providers and appointments.
- Tailoring the course of therapy to your individual requirements and goals.
- Helping you become more knowledgeable and aware of your health.

- Helping you find ways to heal, look for yourself, and keep your independence.
- Keeping you updated on healthcare decisions at all times.

2b. Benefits for schizophrenia patient

A person-centered approach to schizophrenia treatment emphasizes patient values, experiences, and self-management skills, enhancing recovery and quality of life, and enhancing clinical decision-making.[16]

This also includes

- Cognitive behavioural therapy
- Supported education and work
- Educating the family about the condition.

2c. Empowerment and collaboration

In contrast to demoralisation and resignation, empowerment in the psychological area has become a significant role for professionals who emphasise on the voluntary powers, self-realizing strength and financial capacity of individuals as counterforces against problems in critical life circumstances. In order to help their clients regain their autonomy and engage actively in the community, professionals can use the concept of empowerment as a useful tool to remind them of their strengths and abilities, which are frequently overlooked.[19] [20] Increasing values-aligned care is the main goal of collaborative decision making, which places a high priority on patient beliefs, including social norms and outcomes linked to quality of life. It is one instrument to improve access to value-aligned treatment for individuals with significant mental illnesses along with other groups, as well as to restructure interactions between patients and physicians as well as the system..[21]

3. Understanding the unique needs of schizophrenia

Quality of life: The World Health Organisation defines quality of life as an individual's perception of their life position, including goals, expectations, worries, and social surroundings.

Quality of life in relation to health : Health-related quality of life is an individual's comprehensive assessment of how a condition and its treatment impact their psychological, physical, and social aspects.

Function: Functioning refers to a person's ability to perform daily tasks, fulfill obligations, and maintain health, while social functionality encompasses education, housing, role activities, relationships, behavioral functioning, and happiness.[16]

3a. Symptomatology and viability

Negative symptoms must be addressed by managing chronic pain, reducing stigma and self-stigma, offering psychosocial treatments, avoiding sedation and extrapyramidal side effects (EPS), and appropriately treating paranoia, anxiety, depression, and substance use disorders.[16] [4] [6]

3b. Functional impairment

Cognition: Schizophrenia affects all cognitive domains, with procedural memory being consistently present but not pronounced, while other domains show severe disruption.[22] Cognitive dysfunction in schizophrenia can be treated through comorbid mental health conditions, physical illnesses, or environmental factors.

Treatments include cognitive-behavioral therapy, remediation, social skills instruction, and computer-assisted training programs.[23]

3c. Co-occurring conditions

Chronic and debilitating, schizophrenia can be challenging to manage, particularly when it coexists with other disorders including depression and obsessive-compulsive behaviours. Research suggests morphology and FC may be separate in schizophrenia, enhancing understanding of clinical heterogeneity and distinct psychopathology, benefiting academics and clinicians studying the disease.[24] Research indicates genetic diathesis impacts clinical traits, affecting intracellular signaling and neurotransmitter activity. Further investigation is needed to understand calcium channel gene function in severe neurological and psychiatric illnesses.[25] OCD, sadness, dementia, and social anxiety are examples of symptoms that proponents of the comorbidity theory in schizophrenia have suggested may be distinct clinical diseases with their own underlying pathophysiology .[26]

4. Assessment and holistic evaluation

The holistic management of schizophrenia encompasses mainstream pharmaceutical intervention, complementary medicine intervention, therapeutic intervention, and other psychosocial factors, including housing, education, job training, employment, relationships, friendships, exercise, and general well-being, cigarettes, substance abuse, suicide prevention, stigmatisation, entertainment, recreation, violent behaviour, setting up public trusteeship and guardianship, managing medication-related overweight, and other medication-related health complications.[27] .[28]

4a. Psychiatric history and diagnosis

Most psychiatric illnesses have a risk factor associated with a biological relative's history of mental illness. Information can be gathered through direct interviews with each relative (family study) or through informants (family history). Methods for family history or family studies that are currently available might take too much time for genetic research screening, clinical use, or epidemiological studies. All agree that the family history method underreports illness when compared to direct interviews, but that this problem can be partially resolved by using more informants. The lifetime psychiatric history of each family member can be recorded using these instruments in 10 to 50 minutes. The first screening questions for six diagnoses are only asked in the Family History Assessment Module for all relatives collectively. Other self-report screens are not helpful for family history because they use lifetime diagnoses only, not current ones (e.g., multiple DSM-III-R diagnoses). Getting a psychiatric history is similar to getting a medical history, but it focuses more on social and developmental aspects. In addition, a history of family psychiatric illnesses and treatments, as well as the patient's prior mental health history, including medication and treatment, must be included .[29]

4b. Strength and resources

Strengths in patient-centered care for individuals with schizophrenia frequently come from their lived experiences, resilience, and distinct viewpoints. Important components of patient-centered care for schizophrenia include involving the patient in decision-making, creating individualised treatment plans, and creating a supportive environment .[30]

4c. Preferences and values

When giving care or support, it's critical to create a supportive environment, respect their autonomy, and take into account their unique needs and preferences Effective comprehension and reinforcement of these preferences and values can be facilitated by the professional advice and participation of mental health specialists.[32] Effective support for an individual diagnosed with schizophrenia necessitates taking into account their preferences and values .[31]

5. Engaging the patients and establishing trust

- People should be encouraged to actively participate in their own care. Find out about their areas of strength, interests, and current needs. You should also find out how they prefer to be contacted, informed, and supported.
- An individual's direct conversation is the most effective way to learn about their mental health.
- Medical records are just one source of information about a person; they might not be comprehensive or accurately represent that person's mental health at the time.
- Be aware that someone going through psychosis could find it difficult to distinguish between reality and illusion. Recognise that the individual is experiencing very real delusions and/or hallucinations. Never minimise, discount, or argue with someone who has delusions or hallucinations.
- Continue to be kind, patient, and open to communication. Individuals going through psychosis frequently require time to decide on a course of treatment, and they might be more likely to ask for assistance down the road.[33]

5a. Building therapeutic rapport

Building a trustworthy relationship with the patient is important for a variety of reasons. Developing a rapport with individuals who suffer from severe disorders such as schizophrenia is crucial to observing positive change and advancement. The therapeutic alliance is intricate. It entails building trust, encouraging empathy, facilitating clear communication, encouraging group decision-making, and maintaining professional boundaries—aspects that ought to be at the core of every therapist's practise.[34].[35]

5b. Active listening and validation

One technique for identifying and examining patients' cues is active listening. Health care providers frequently fail to identify patients' true concerns when they lack this communication skill. To find different kinds of clues, qualitative methods like post-interview debriefing, videotape analysis, and interpersonal process recall were employed.

The taxonomy of clues consists of the following:

(1) Feelings expressed, especially fear or anxiety

(2) Efforts to understand or interpret symptoms

(3) Spoken cues that draw attention to particular issues brought up by patient;

(4) Personal narratives that connect a patient to hazards or illnesses

By employing this hint taxonomy, physicians may more easily recognise their patients' clues, which will help them become more skilled at actively listening.[36] Patient satisfaction should rise and outcomes should improve with a better understanding of the underlying reasons for the visit. Seven Ways to Establish Comfort with Patients:

1. Maintaining eye contact
2. Express Empathy
3. Honest Talking
4. Individualise it
5. Paying Attention
6. Take up mirroring.
7. Honour your commits [36] [37]
8. Involving the patient in treatment care plan.[38][39].[40]

6. Shared decision-making and goal setting

Shared decision making (SDM) involves patients and healthcare providers working together to make decisions based on patient preferences and available data, reducing conflict and increasing patient satisfaction, promoting patient autonomy. Following the completion of a thorough examination, a treatment plan will be developed.[41] It is expected of service intake clinicians to find out during the intake and assessment sessions what the patient hopes to accomplish by attending the service (goals).[42]

6a.Identifying treatment goals

The goals of treatment for individuals with schizophrenia are numerous. The patient and the doctor perspectives are the two main ones regarding the objectives of treatment. The objectives of schizophrenia treatment for patients are reduction of schizophrenia's positive and negative symptoms lowering ancillary symptoms like anxiety reducing the possibility that additional disorders, like substance abuse or depression, will manifest.[44].[43]

6b.Prioritizing patient preferences

Depression often goes untreated, especially in the elderly and minority communities. Patient preference data can aid in patient-centric decision-making, benefit-risk evaluations, and advocacy.[45] [46]

6c. Setting realistic expectations

It's critical to acknowledge the difficulties that schizophrenia presents. Assist the patient in reaching realistic objectives, and exercise patience as their recuperation progresses. Consider engaging in activities like reading, walking, listening to music, or drawing. Helping the patient manage these symptoms requires keeping them engaged in activities that are grounded in reality.[46]

7. Tailoring treatment plans:

Schizophrenia patients require individualised treatment plans that take into account their unique symptoms, reaction to medication, side effects, and preferences. Antipsychotic drugs, psychotherapy, social support, and occasionally rehabilitation programmes are all part of it. Given the complexity of schizophrenia, treatment plans must be customised for each patient.

Here are some essential elements of treating each patient as an individual:

1. **Medication Administration**
2. **Psychotherapy**
3. **Social Assistance**
4. **Rehabilitation Programmes**
5. **Regular Monitoring and Evaluation**
6. **Shared Decision-Making**

To address the particular needs and circumstances of each person with schizophrenia, it is imperative to customise these components in a personalised treatment plan. Developing and modifying these treatment plans requires consulting with medical professionals skilled in the management of schizophrenia.[47] An all-inclusive, person-centered treatment plan aims to improve functioning, reduce symptoms, and treat co-occurring mental illnesses, incorporating both pharmaceutical and nonpharmacological treatments for maximum results. The following could be included as additional components of the treatment plan:

•selecting the ideal setting for therapy.
•Eliminating barriers compliance.
• Status of insurance
• Participation in the legal system
• Deciding on additional needs
•Cooperating with other healthcare providers.[48]

7a.Pharmacological interventions:

Schizophrenia treatment remains challenging despite medication advances. Effectiveness metrics and measurement-based approaches are needed. Second-generation antipsychotics may offer better results due to decreased side effects and relapse rates.[49]

7a.1. Antipsychotic medications:

Antipsychotics, created in 1952, are the primary pharmaceutical treatment for schizophrenia and mood disorders. Despite their origins, extensive research has been conducted to determine their exact mechanism of action. Antipsychotics are classified as typical or atypical based on their motor adverse effects, predominant action at dopamine D2R, and multimodal activity at other receptor classes. However, little is known about how these medications impact intracellular processes, starting with receptor occupancy.[50] Relapse rates in maintenance patients range from 18% to 32%, while in patients not on maintenance therapy, they range from 60% to 80%. Medication therapy should be continued for at least a year after the first psychotic episode resolves. The American Psychiatric Association recommends second-generation antipsychotics (sgas) as the first line of therapy, except for clozapine, which is not advised due to agranulocytosis. Sgas are often preferred over fgas due to their association with less extrapyramidal symptoms and are often linked to metabolic adverse effects like diabetes mellitus, weight gain, and hyperlipidemia, which may contribute to higher cardiovascular mortality in schizophrenia patients.

The Texas Medication Algorithm Project (TMAP) offers a six-stage pharmacotherapeutic algorithm for schizophrenia treatment. Stage 1 involves first-line monotherapy using an SGA. If no response is seen, the patient should proceed to Stage 2, which involves monotherapy with another SGA or a FGA. If no improvement is seen, the patient should proceed to Stage 4, which combines clozapine with a FGA, an SGA, or electroconvulsive therapy (ECT). If no improvement is seen, stage 5 treatment is required.[50] [1]

7a2.Adjunctive therapy:

Patients who do not respond well to clozapine may be offered both combination therapy (using antipsychotics) and adjunctive therapy (ECT or mood stabilizers). The following recommendations should be followed by clinicians when providing adjunctive therapy.Adjunctive therapies refer to a variety of methods used in addition to standard treatments for schizophrenia. Here's a couple more:

1. Social Support Programmes
2. Nutritional Support
3. Practises for Mindfulness and Stress Reduction
4. Family Therapy
5. Rehabilitative .[51]

7b. Psychosocial intervention:
Social skill development, psychoeducation, family therapy, cognitive behavioural therapy, cognitive remediation therapy, and vocational rehabilitation fall under this area. It can be applied to improve the therapy.[51]

7b1. Cognitive behavioural therapy:
Cognitive behavioural therapy (CBT) is a goal-oriented, organized talk therapy used to treat schizophrenic patients, as recommended by the National Institute for Health and Care Excellence (NICE). CBT for psychosis (cbtp) aims to help patients understand and normalize their illness experiences, enhance functioning, and reduce suffering.[51]

7b2. Family intervention:
Family intervention make it easier to handle conflicts and contradictions, improve communication, and strengthen ties within the family. Studies have demonstrated a relationship between the recurrence rate and the feelings that patients' relatives communicate. Patients who live in homes where there is a lot of hostility, criticism, and over-involvement are more likely to relapse. Thus, family intervention may enhance medication compliance and lower the risk of relapses and rehospitalisation by lowering expressed emotion and stress within the family. Relapse and hospital admission rates may be decreased by family interventions.[51]

7b3. Supported employment and education
Between the ages of 16 and 30, when people are usually establishing their educational, professional, and job paths, psychosis often begins. Access to team-based early invention services for psychosis, such as supported education and employment (SEE) programmes, is made possible through coordinated specialty care (CSC) programmes. Over the course of ontrackny participation, rates of involvement in employment and education rose. Customers who participated less in work or school were more likely to use SEE services. For clients under 23, receiving supported education services is linked to higher first-year school attendance. However, when looking at people who used both at the same time, this association is inconsistent and only significant in the first quarter for supported employment services.[52]

7b4. Social skills training:
Most people with schizophrenia have seen a decrease in their social functioning and have been socially isolated to varied degrees because of stigma associated with mental illnesses, prolonged hospital stays, and persistently unfavourable symptoms. Thus, behavioural strategies like as role play, modelling, coaching, and feedback are often used in social skill training to help patients resolve interpersonal connection problems and express themselves correctly. The primary objective of social skills training is to enhance social functioning in persons diagnosed with psychosis.[51]

8. Cultural competence and sensitivity

In order to diagnose and treat patients from different cultural backgrounds effectively, healthcare professionals must be able to work well with them by taking into consideration their unique needs, behaviours, and beliefs. This requires cultural competence. The significance of providing a culturally sensitive response to a patient's concerns must be understood by the entire healthcare team. Examining one's unconscious presumptions about how one should respond to a patient's cultural background can help reduce prejudice and enhance the way healthcare is provided. It's also important to gently elicit cultural information to improve your relationship with the patient and their family.[54]

But as of right now, we know that culture plays a variety of roles in how psychopathology manifests itself. They are listed below:

- **Pathogenic effects**
- **Patho-selective effects**
- **Patho-plastic effect**
- **Patho –elaboration effects**
- **Patho-facilitative effects**
- **Patho-reactive effects** .[53]

8a. Addressing Cultural influences on perception and treatment

Cultural factors have a big impact on how people see and treat schizophrenia. Variations in cultural beliefs, stigma, and explanatory models impact the interpretation and management of symptoms. Cultural factors are important in determining how schizophrenia is understood and interpreted. For example, delusions or hallucinations may be considered spiritual experiences in certain cultures, but they may also be considered a serious mental illness in others. This difference may have an impact on the way that people or families seek therapy, whether through conventional psychiatric care, traditional healers, or religious leaders.[55]. Individuals with schizophrenia living in diverse cultural contexts can greatly benefit from treatment adherence and outcomes that are tailored to acknowledge and incorporate cultural factors.[56]

8b.Culturally appropriate communication

Understanding and honoring the cultural norms, beliefs, and communication preferences of the person with schizophrenia is essential to culturally competent communication. This could entail taking into account linguistic preferences, spirituality or religion, family dynamics, and the effects of societal stigmas associated with mental health. Communication strategies must be adjusted to account for cultural differences in order to effectively support the person with schizophrenia and promote trust and understanding. Communicating with someone who has schizophrenia in a culturally appropriate manner entails showing a great deal of respect for cultural diversity, acknowledging how it affects the person's experience of the illness, and modifying communication and treatment plans to better fit the patient's needs within their cultural context.[57]

8c. Involving and community support

Fostering a sense of belonging, promoting participation, and advancing the well-being of individuals within a community all depend on community support and involvement. Opportunities for volunteer work, interesting gatherings, honest dialogue, and projects that deal with community issues and needs can all help achieve this. In a community, being actively involved cultivates a strong sense of empowerment and connection.[57] [58]

9. Promoting adherence and self-management

The prognosis of individuals with serious mental illnesses can be improved with proper medication and psychosocial treatments. However, a third of these individuals stop receiving treatment. Risk factors for treatment dropout include male gender, early onset psychosis, low social functioning, racial/ethnic minority origin, younger age, and co-occurring psychiatric and drug use disorders. The use of technology in mental health treatment can be ambivalent, causing emotional resistance, shifting patients' burdens to self-care, and requiring unseen work from healthcare professionals. Further investigation is needed to understand and resolve these potential obstacles.[59]

9a. Psychoeducation and schizophrenia

To assist patients better comprehend their disease and the treatment they are receiving, psychoeducational interventions have been developed. It is believed that those who have schizophrenia will be able to control their illness more skillfully and that this will improve their prognosis. The results raise the possibility that psychoeducation improves social function and has a beneficial impact on an individual's well-being. In the medium run, one additional patient demonstrated a clinical improvement when four individuals with schizophrenia were treated with psychoeducation rather than standard care.[60]

9b. Medication management and adherence strategies

.However, this process is made more difficult by their limited perspective, the stigma associated with the diagnosis, and the frequently unsettling side effects of antipsychotic medication. Encouragement of accepting the illness, comparisons with treatments for chronic illnesses, and patient involvement in decision-making are some interventions to increase adherence. The choice of antipsychotic medication is essential to prevent negative side effects, and certain drugs may improve symptoms of depression, anxiety, or insomnia while also promoting a sense of wellbeing. Depot antipsychotics, as opposed to oral ones, can enhance adherence and give the doctor accurate information regarding the patient's dosage, which can be utilised to modify the medication or plan a response to relapse.[59] [61]

9c. Coping skills and healthcare techniques:

Emotional coping moderates the association between life satisfaction and anxiety/depression symptoms, while avoidance-oriented coping influences the relationship between paranoid symptoms and life happiness. Coping mechanisms also influence life satisfaction, self-construct factors, emotional discomfort, and dysphoric mood. Patients with schizophrenia spectrum illnesses and mental health professionals can use quality of life and coping mechanisms as important information sources. The use of both constructive and destructive coping strategies is connected to the subjective evaluation of psychopathology. The greatest characteristics correlated with the total Q-LES-Q score include subjective CGI, positive coping methods, the difference between objcgi and subjcgi, and negative coping strategies.
.[62]

10. Monitoring progress and adjustment treatment

The act of performing scheduled serial measurements of specific parameters on a regular basis is known as monitoring. Tables and charts are then used to document the values or results. Complete monitoring must be carried out from the start of treatment and should only stop if the illness is thought to be cured or if treatment has been stopped. Both positive and negative outcomes are possible from treatment.

Periodically, measurements of some parameters may stop being taken if they are no longer useful, such as when the patient has stabilised, and measurements of other parameters may take their place.[63] In the context of treating schizophrenia, tracking development entails evaluating multiple factors:

1. Symptoms
2. Functional status
3. Side effects
4. Medication adherence
5. Therapeutic interventions

Treatment adjustments could entail:

1. **Medication changes:** Changing prescriptions or adjusting dosages to better control symptoms and minimise adverse effects.
2. **Therapy adjustments:** Adding or changing therapeutic modalities to address particular symptoms or functional challenges.
3. **Psychoeducation:** Informing the patient and those close to them about the illness, available treatments, and coping mechanisms.

Respecting the patient's autonomy and giving them the assistance they need to be well is crucial.[64]

10a. Regular assessments and outcome measures

Frequent evaluations and outcome measures are crucial in the treatment of schizophrenia to track the patient's development. These may include cognitive tests, functional assessments, clinical interviews, and symptom rating scales. Monitoring symptoms, medication response, and general health helps customize care and support. Routinely using outcome measures, such as mental state assessment scales, enhances patient care and decision-making. Over the past 30 years, 'patient-based measures' have become increasingly important, measuring clinical features of sickness and assessing the personal impact of a condition. These tools, sometimes called health status, functional status measurements, or health-related quality of life (hrqol), evaluate more than just clinical symptoms, encompassing overall views of health and well-being, social and role functioning, physical and mental health, cognitive capacity, and patient satisfaction.[65] In schizophrenia, routine evaluations fulfil a number of important functions:

1. Symptom Monitoring
2. Cognitive Function Evaluation
3. Functional and Social Assessments
4. Medication and Side Effects Monitoring
5. Long-term Outcome Measures

Clinicians can develop customized treatment plans, monitor patients' progress, and modify interventions to better meet patients' needs and improve their quality of life by routinely using these assessments.[64] [65]

10b. Feedback loops with the patient

In order to evaluate and address symptoms and treatment efficacy, feedback loops entail interactions between the patient, their surroundings, and mental health professionals. Continuous feedback enhances overall care and condition management by enabling the individual to receive support and treatments tailored to their needs.[66]

Feedback loops in the treatment of schizophrenia usually entail continuous evaluation and communication between the patient, their therapist, psychiatrist, and support system. Optimising symptom management and raising the patient's standard of living are the two main objectives.[67] [68]

10c. Flexibility in treatment plans

Schizophrenia is a condition that varies in person and each person responds differently to treatments, therefore treatment plans must be flexible. Often, therapy, medication, and support services are used in combination for treatment. Treatment plans for schizophrenia can be flexible in a number of ways:

- **Medication Adjustments**
- **Therapy Options**
- **Lifestyle Modifications**
- **Support Services**
- **Regular Assessment and Re-evaluation**.
- **Involvement of the Patient and Carers** [69]

11. Patient centered outcomes and quality of life

Response, remission, and recovery are three categories into which treatment outcomes for schizophrenia can be categorized.

Response: Response is commonly understood to be a percentage decrease in symptoms from baseline. The Positive and Negative Syndrome Scale (PANSS) or the Brief Psychiatric Rating Scale (BPRS) are commonly used to measure this decrease.

Remission: For the purpose of guaranteeing patient well-being, clinicians need a clear cut threshold for symptoms. The criteria that Andreasen et al. Proposed in 2005 for a consensual definition of remission in schizophrenia. It was suggested that specific symptom items be used to assess good and negative symptoms on the following scales:

According to the Scale for the Assessment of Negative Symptoms (SANS), items 7 (affective flattening), 17 (avolition/apathy), 22 (anhedonia/asociality), and 13 (alogia) and items 20 (delusions), 7 (hallucinations), 34 (positive formal thought disorder), and 25 (bizarre behaviour) are categorised as positive symptoms. The SANS PANSS assesses the following: G5 (mannerisms/posturing), N1 (blunted affect), N4 (social disengagement), and N6 (lack of spontaneity). P1-3 (delusions, conceptual disorganisation, hallucinatory behaviour) are measured. Eight are grandiosity, eleven are suspiciousness, fifteen are unique mental content, twelve are hallucinatory conduct, four are conceptual disorganisation, seven are mannerisms/posturing, and sixteen are muted affect.

Perhaps the most sensible and accessible alternative is the PANSS, as it uses a single scale to rate both positive and negative symptoms. Remission is characterised by moderate or lower ratings on all items maintained for a minimum of six months using any of the previously described methods

Recovery: Recovery is the most sought-after result of treatment. According to Liberman et al.©, recovery is defined as the patient maintaining the following traits for at least two years: .[70]

Symptom Remission:

Vocational functioning includes employment, education, and age-appropriate activities for those who are retired.A patient-centered approach is crucial for evaluating the effectiveness of therapy for schizophrenia patients. This includes considering patient-centered treatment goals, such as functioning, quality of life, and health-related quality of life. Patient-reported outcomes are crucial for assessing the illness's impact and treatment effectiveness. Successful treatment addresses multiple schizophrenia domains while avoiding nonadherence-related adverse events, ensuring recovery, satisfactory quality of life, and appropriate functionality.[71]

11a. Assessing patient reported outcomes

Evaluations of patient-reported outcomes are becoming more common in the assessment of schizophrenia treatment. Patient-reported outcomes in schizophrenia pertain to self-resilience or the assessment of illness and treatment benefit. The most prevalent of the former are treatment satisfaction, care needs, and the therapeutic alliance. Symptoms, insight, attitude towards medicine, and clinical communication are less common. In response to growing treatment expectations, new resilience measures have been established, including empowerment, self-esteem, feeling of coherence, and recovery. Mood has a significant influence on the general propensity for more or less positive assessment, which affects the scores of several patient-related outcomes that overlap.[72] Patient-reported outcomes are widely utilised in mental health studies to assess the therapy benefits for patients. The US Food and Drug Administration defines them as "any report coming directly from patients (i.e. Study subjects) about a health condition and its treatment" (2006). Therefore, any outcome that is decided by the patient alone, without the aid of a researcher or physician, and is predicated on the patient's evaluation of their health and treatment plan is a patient-reported outcome. A single-item or multi-item measure can be used to evaluate a patient-reported outcome, which offers a way to gauge the effectiveness of treatment by capturing ideas about how an individual feels or operates in relation to their health. We refer to a subjective evaluation criterion—a method of assessing care that is directly based on and represents the opinions, feelings, and judgements of the patient—as a patient-reported outcome.[73]

11b. Tracking functional gains and milestone

Schizophrenia is a severe mental disorder that often results in patients unable to function due to failure to meet real-world functional goals. Functional successes include educational attainment, housing independence, work status, marital status, and social contacts. Younger patients have higher functional capacity, and women are more likely to reach higher milestones. Classifying symptoms into positive, negative, and generic domains can help improve patient outcomes.[74]

11 c. Enhancing well-being and satisfaction

A comprehensive strategy that includes individualised care, psychoeducation, medication management, therapy (such as cognitive-behavioural therapy), social support, lifestyle modifications, and promoting a cooperative relationship between patients, carers, and healthcare professionals is necessary to improve well-being and satisfaction in patient-centered treatment for schizophrenia.

Strategies that can improve satisfaction and well-being in schizophrenia patient-centered treatment:

1. Individualised Care.
2. Psychoeducation
3. Medication Management
4. Therapeutic Interventions
5. Social Support and Rehabilitation
6. Lifestyle modifications
7. **Shared Decision- Making**
8. Crisis Management Plan
9. Ongoing Evaluation and Support .[75]

Conclusion

Negative symptoms and cognitive impairment are experienced by around 40% and 80% of people with schizophrenia, respectively, and have a direct impact on functional results and the total burden of disease. Techniques for defining, measuring, and managing these symptom domains are relevant. This article describes the phenomenology, prevalence, assessment, and treatment of negative and cognitive symptoms in individuals with schizophrenia. There are currently no licensed therapies for schizophrenia that address negative or cognitive symptomatology. Future research into the neurobiology of these significant schizophrenia symptom domains will aid in developing successful treatment plans. Physicians should avoid therapeutic nihilism and focus on recognizing, quantifying, and monitoring the severity and outcomes of cognitive and psychological symptoms. Psychosocial therapy, cognitive behavioural therapy, cognitive remediation, computer-assisted training programs, social skills training, and antipsychotic medication should be offered in addition to cognitive behavioural therapy, cognitive remediation, computer-assisted training programs, social skills training, and antipsychotic medication. Treatment regimens should be adjusted over time and based on individual needs to enhance overall results.

In addition to positive symptoms, improving outcomes for patients with schizophrenia requires symptom management in additional clinical areas. Patient-reported outcomes are essential for assessing the impact of the illness and the effectiveness of its treatment. Pharmacotherapy combined with psychosocial therapies that address social skills, family dynamics, cognitive function, and occupational rehabilitation is likely to produce the best outcomes. New medications are needed to treat the complex condition of schizophrenia.

Reference

1.Patel KR, Cherian J, Gohil K, Atkinson D. Schizophrenia: overview and treatment options. P T. 2014 Sep;39(9):638-45. PMID: 25210417; PMCID: PMC4159061.
2.Jablensky A. The diagnostic concept of schizophrenia: its history, evolution, and future prospects. Dialogues Clin Neurosci. 2010;12(3):271-87. Doi: 10.31887/DCNS.2010.12.3/ajablensky. PMID: 20954425; PMCID: PMC3181977.

3.Julie Kreyenbuhl, Ilana R. Nossel, Lisa B. Dixon, Disengagement From Mental Health Treatment Among Individuals With Schizophrenia and Strategies for Facilitating Connections to Care: A Review of the Literature, Schizophrenia Bulletin, Volume 35, Issue 4, July 2009, Pages 696–703, https://doi.org/10.1093/schbul/sbp046
4.Jauhar, S., mckenna, P., Radua, J., Fung, E., Salvador, R., & Laws, K. (2014). Cognitive–behavioural therapy for the symptoms of schizophrenia: Systematic review and meta-analysis with examination of potential bias. The British Journal of Psychiatry, 204(1), 20-29. Doi:10.1192/bjp.bp.112.116285
5.Chien WT, Leung SF, Yeung FK, Wong WK. Current approaches to treatments for schizophrenia spectrum disorders, part II: psychosocial interventions and patient-focused perspectives in psychiatric care. Neuropsychiatr Dis Treat. 2013;9:1463-81. Doi: 10.2147/NDT.S49263. Epub 2013 Sep 25. PMID: 24109184; PMCID: PMC3792827.
6.Correll CU. Pharmakotherapie der Schizophrenie [Pharmacotherapy of schizophrenia]. Nervenarzt. 2020 Jan;91(1):34-42. German. Doi: 10.1007/s00115-019-00858-z. PMID: 31919550.
7.Irwin KE, Park ER, Fields LE, Corveleyn AE, Greer JA, Perez GK, Callaway CA, Jacobs JM, Nierenberg AA, Temel JS, Ryan DP, Pirl WF. Bridge: Person-Centered Collaborative Care for Patients with Serious Mental Illness and Cancer. Oncologist. 2019 Jul;24(7):901-910. Doi: 10.1634/theoncologist.2018-0488. Epub 2019 Jan 29. PMID: 30696722; PMCID: PMC6656464.
8.Rudnick, A., & Roe, D. (1960). Serious Mental Illness: Person-Centered Approaches (1st ed.). CRC Press. Https://doi.org/10.4324/9781315384054
9.mccabe R, Saidi M, Priebe S. Patient-reported outcomes in schizophrenia. Br J Psychiatry Suppl. 2007 Aug;50:s21-8. Doi: 10.1192/bjp.191.50.s21. PMID: 18019040.
10.Corring DJ, Cook JV. Client-centred care means that I am a valued human being. Can J Occup Ther. 1999 Apr;66(2):71-82. Doi: 10.1177/000841749906600203. PMID: 10605157.
11.Rosemarie mccabe, Patrick G.T. Healey, Stefan Priebe, Mary Lavelle, David Dodwell, Richard Laugharne, Amelia Snell, Stephen Bremner,Shared understanding in psychiatristâ€“patient communication: Association with treatment adherence in schizophrenia,Patient Education and Counseling,Volume 93, Issue 1,2013,Pages 73-79,ISSN 0738-
3991,https://doi.org/10.1016/j.pec.2013.05.015.(https://www.sciencedirect.com/science/article/pii/S0738399113002152)
12. Lobban F, Barrowclough C, Jones S. Assessing cognitive representations of mental health problems. I. The illness perception questionnaire for schizophrenia. Br J Clin Psychol. 2005 Jun;44(Pt 2):147-62. Doi: 10.1348/014466504X19497. PMID: 16004651.
13.Davis K, Schoenbaum SC, Audet AM. A 2020 vision of patient-centered primary care. J Gen Intern Med. 2005 Oct;20(10):953-7. Doi: 10.1111/j.1525-1497.2005.0178.x. PMID: 16191145; PMCID: PMC1490238.
14. Harvey PD. Patient-Centered Treatment Strategies to Improve Outcomes in Schizophrenia. The Journal of Clinical Psychiatry. 2021 Mar;82(2):IC20018BR2C. DOI: 10.4088/jcp.ic20018br2c. PMID: 34033268.
15.Stanghellini G, Bolton D, Fulford WK. Person-centered psychopathology of schizophrenia: building on Karl Jaspers' understanding of patient's attitude toward his illness. Schizophr Bull.

2013 Mar;39(2):287-94. Doi: 10.1093/schbul/sbs154. Epub 2013 Jan 11. PMID: 23314193; PMCID: PMC3576158.
16. Kuipers, S.J., Cramm, J.M. & Nieboer, A.P. The importance of patient-centered care and co-creation of care for satisfaction with care and physical and social well-being of patients with multi-morbidity in the primary care setting. BMC Health Serv Res 19, 13 (2019). Https://doi.org/10.1186/s12913-018-3818-y
17.Reynolds A. Patient-centered Care. Radiol Technol. 2009 Nov-Dec;81(2):133-47. PMID: 19901351.
18.Sanya Grover, Aoife Fitzpatrick, Farah Tabassum Azim, Patrocinio Ariza-Vega, Paule Bellwood, Jane Burns, Elissa Burton, Lena Fleig, Lindy Clemson, Christiane A. Hoppmann, Kenneth M. Madden, Morgan Price, Dolores Langford, Maureen C. Ashe,Defining and implementing patient-centered care: An umbrella review,Patient Education and Counseling,Volume 105, Issue 7,2022,Pages 1679-1688,ISSN 0738-3991,https://doi.org/10.1016/j.pec.2021.11.004.(https://www.sciencedirect.com/science/article/pii/S0738399121007254)
19.Pulvirenti M, mcmillan J, Lawn S. Empowerment, patient centred care and self-management. Health Expect. 2014 Jun;17(3):303-10. Doi: 10.1111/j.1369-7625.2011.00757.x. Epub 2012 Jan 2. PMID: 22212306; PMCID: PMC5060728.
20.Chamberlin, J. (1997). A working definition of empowerment. Psychiatric Rehabilitation Journal, 20(4), 43–46.
21.Corrigan, P. W., & Calabrese, J. D. (2005). Strategies for Assessing and Diminishing Self-Stigma. In P. W. Corrigan (Ed.), On the stigma of mental illness: Practical strategies for research and social change (pp. 239–256). American Psychological Association. Https://doi.org/10.1037/10887-011
22.Pennington C, Ball H, Swirski M. Functional Cognitive Disorder: Diagnostic Challenges and Future Directions. Diagnostics (Basel). 2019 Sep 28;9(4):131. Doi: 10.3390/diagnostics9040131. PMID: 31569352; PMCID: PMC6963804.
23.mccutcheon, R.A., Keefe, R.S.E. & mcguire, P.K. Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment. Mol Psychiatry 28, 1902–1918 (2023). Https://doi.org/10.1038/s41380-023-01949-9
24.Abdullah HM, Azeb Shahul H, Hwang MY, Ferrando S. Comorbidity in Schizophrenia: Conceptual Issues and Clinical Management. Focus (Am Psychiatr Publ). 2020 Oct;18(4):386-390. Doi: 10.1176/appi.focus.20200026. Epub 2020 Nov 5. PMID: 33343250; PMCID: PMC7725147.
25.Fenton, Wayne S.. Comorbid conditions in schizophrenia. Current Opinion in Psychiatry 14(1):p 17-23, January 2001.
26.Buckley PF, Miller BJ, Lehrer DS, Castle DJ. Psychiatric comorbidities and schizophrenia. Schizophr Bull. 2009 Mar;35(2):383-402. Doi: 10.1093/schbul/sbn135. Epub 2008 Nov 14. PMID: 19011234; PMCID: PMC2659306.
27.AUTHOR=Ganguly Pronab, Soliman Abdrabo, Moustafa Ahmed A.TITLE=Holistic Management of Schizophrenia Symptoms Using Pharmacological and Non-pharmacological Treatment JOURNAL=Frontiers in Public Health VOLUME=6 YEAR=2018 URL=https://www.frontiersin.org/articles/10.3389/fpubh.2018.00166
DOI=10.3389/fpubh.2018.00166

28.Ganguly, P., & Moustafa, A. A. (2018). A survey towards holistic management of schizophrenia. Psychology Research, 8(6), 263-281. Https://doi.org/doi:10.17265/2159-5542/2018.06.003
29. Mortensen, P., Pedersen, M., & Pedersen, C. (2010). Psychiatric family history and schizophrenia risk in Denmark: Which mental disorders are relevant? Psychological Medicine, 40(2), 201-210. Doi:10.1017/S0033291709990419
30. Kessler, R. C. (2000). Some considerations in making resource allocation decisions for the treatment of psychiatric disorders. In G. Andrews & S. Henderson (Eds.), Unmet need in psychiatry: Problems, resources, responses (pp. 59–84). Cambridge University Press. Https://doi.org/10.1017/CBO9780511543562.007
31.Stanghellini G, Ballerini M. Values in persons with schizophrenia. Schizophr Bull. 2007 Jan;33(1):131-41. Doi: 10.1093/schbul/sbl036. Epub 2006 Aug 29. PMID: 16940339; PMCID: PMC2632282.
32.Fifer S, Keen B, Newton R, Puig A, mcgeachie M. Understanding the Treatment Preferences of People Living with Schizophrenia in Australia; A Patient Value Mapping Study. Patient Prefer Adherence. 2022 Jul 19;16:1687-1701. Doi: 10.2147/PPA.S366522. PMID: 35898923; PMCID: PMC9309312.
33. Bombard, Y., Baker, G.R., Orlando, E. Et al. Engaging patients to improve quality of care: a systematic review. Implementation Sci 13, 98 (2018). Https://doi.org/10.1186/s13012-018-0784-z
34.Westermann S, Cavelti M, Heibach E, Caspar F. Motive-oriented therapeutic relationship building for patients diagnosed with schizophrenia. Front Psychol. 2015 Sep 2;6:1294. Doi: 10.3389/fpsyg.2015.01294. PMID: 26388804; PMCID: PMC4557062.
35. Hewitt, Jeanette & Coffey, Michael. (2006). Therapeutic working relationships with people with schizophrenia: Literature review. Journal of advanced nursing. 52. 561-70. 10.1111/j.1365-2648.2005.03623.x.
36. Lang F, Floyd MR, Beine KL. Clues to patients' explanations and concerns about their illnesses. A call for active listening. Arch Fam Med. 2000 Mar;9(3):222-7. Doi: 10.1001/archfami.9.3.222. PMID: 10728107.
37. Bodie, Graham & Vickery, Andrea & Cannava, Kaitlin & Jones, Susanne. (2015). The Role of "Active Listening" in Informal Helping Conversations: Impact on Perceptions of Listener Helpfulness, Sensitivity, and Supportiveness and Discloser Emotional Improvement. Western Journal of Communication. 79. 151-173. 10.1080/10570314.2014.943429.
38. Tracy Higgins, Elaine Larson, Rebecca Schnall,Unraveling the meaning of patient engagement: A concept analysis,Patient Education and Counseling,Volume 100, Issue 1,2017,Pages 30-36,ISSN 0738-3991,https://doi.org/10.1016/j.pec.2016.09.002. (https://www.sciencedirect.com/science/article/pii/S0738399116304098)
39. Vahdat S, Hamzehgardeshi L, Hessam S, Hamzehgardeshi Z. Patient involvement in health care decision making: a review. Iran Red Crescent Med J. 2014 Jan;16(1):e12454. Doi: 10.5812/ircmj.12454. Epub 2014 Jan 5. PMID: 24719703; PMCID: PMC3964421.
40. Al-Tannir, M., algahtani, F., Abu-Shaheen, A. Et al. Patient experiences of engagement with care plans and healthcare professionals' perceptions of that engagement. BMC Health Serv Res 17, 853 (2017). Https://doi.org/10.1186/s12913-017-2806-y

41.Haugom, E.W., Stensrud, B., Beston, G. Et al. Experiences of shared decision making among patients with psychotic disorders in Norway: a qualitative study. BMC Psychiatry 22, 192 (2022). Https://doi.org/10.1186/s12888-022-03849-8
42.Cairns, A.J., Kavanagh, D.J., Dark, F. Et al. Goal setting improves retention in youth mental health: a cross-sectional analysis. Child Adolesc Psychiatry Ment Health 13, 31 (2019). Https://doi.org/10.1186/s13034-019-0288-x
43. Fitzgerald HM, Shepherd J, Bailey H, Berry M, Wright J, Chen M. Treatment Goals in Schizophrenia: A Real-World Survey of Patients, Psychiatrists, and Caregivers in the United States, with an Analysis of Current Treatment (Long-Acting Injectable vs Oral Antipsychotics) and Goal Selection. Neuropsychiatr Dis Treat. 2021 Oct 21;17:3215-3228. Doi: 10.2147/NDT.S330936. PMID: 34707359; PMCID: PMC8544790.
44. Gründer G, Bauknecht P, Klingberg S, Leopold K, Paulzen M, Schell S, Stengler K, Leucht S. Treatment Goals for Patients with Schizophrenia – A Narrative Review of Physician and Patient Perspectives. Pharmacopsychiatry. 2021 Mar;54(2):53-59. Doi: 10.1055/a-1298-4546. Epub 2020 Dec 8. PMID: 33291156.
45. Beusterien K, Chan E, Such P, de Jong Laird A, Heres S, Amos K, Loze JY, Nylander AG, Robinson P, Bridges JFP. Development of a stated-preference instrument to prioritize treatment goals in recent onset schizophrenia. Curr Med Res Opin. 2017 Dec;33(12):2129-2136. Doi: 10.1080/03007995.2017.1384717. Epub 2017 Oct 12. PMID: 28945106.
46. Jonas D, Mansfield AJ, Curtis P, et al. Identifying Priorities for Patient-Centered Outcomes Research for Serious Mental Illness [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2011 Sep. Available from: https://www.ncbi.nlm.nih.gov/sites/books/NBK83633/
47. Keepers GA, Fochtmann LJ, Anzia JM, Benjamin S, Lyness JM, Mojtabai R, Servis M, Walaszek A, Buckley P, Lenzenweger MF, Young AS, Degenhardt A, Hong SH; (Systematic Review). The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia. Focus (Am Psychiatr Publ). 2020 Oct;18(4):493-497. Doi: 10.1176/appi.focus.18402. Epub 2020 Nov 5. PMID: 33343262; PMCID: PMC7725162.
48. Grover S, Chakrabarti S, Kulhara P, Avasthi A. Clinical Practice Guidelines for Management of Schizophrenia. Indian J Psychiatry. 2017 Jan;59(Suppl 1):S19-S33. Doi: 10.4103/0019-5545.196972. PMID: 28216783; PMCID: PMC5310098.
49.Kane JM, Correll CU. Pharmacologic treatment of schizophrenia. Dialogues Clin Neurosci. 2010;12(3):345-57. Doi: 10.31887/DCNS.2010.12.3/jkane. PMID: 20954430; PMCID: PMC3085113.
50. De Bartolomeis A, Barone A, Begni V, Riva MA. Present and future antipsychotic drugs: A systematic review of the putative mechanisms of action for efficacy and a critical appraisal under a translational perspective. Pharmacol Res. 2022 Feb;176:106078. Doi: 10.1016/j.phrs.2022.106078. Epub 2022 Jan 10. PMID: 35026403.
51.Sun, Xiaoying & Yue, Suping & Duan, Mingjun & Yao, Dezhong & Luo, Cheng. (2023). Psychosocial intervention for schizophrenia. Brain-Apparatus Communication: A Journal of Bacomics. 2. 1-11. 10.1080/27706710.2023.2178266.
52. Humensky JL, Nossel I, Bello I, Dixon LB. Supported Education and Employment Services for Young People with Early Psychosis in ontrackny. J Ment Health Policy Econ. 2019 Sep 1;22(3):95-108. PMID: 31811753; PMCID: PMC6902640.

53. Viswanath B, Chaturvedi SK. Cultural aspects of major mental disorders: a critical review from an Indian perspective. Indian J Psychol Med. 2012 Oct;34(4):306-12. Doi: 10.4103/0253-7176.108193. PMID: 23723536; PMCID: PMC3662125.
54. Fogel A, Nazir S, Hirapara K, et al. Cultural Assessment And Treatment Of Psychiatric Patients. [Updated 2022 Sep 26]. In: statpearls [Internet]. Treasure Island (FL): statpearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK482311/
55. Rathod S, Kingdon D, Phiri P, Gobbi M. Developing culturally sensitive cognitive behaviour therapy for psychosis for ethnic minority patients by exploration and incorporation of service users' and health professionals' views and opinions. Behav Cogn Psychother. 2010 Oct;38(5):511-33. Doi: 10.1017/S1352465810000378. Epub 2010 Jul 15. PMID: 20630118.
56. Social and Cultural Influences on psychopathologyannual Review of psychologyvol. 29:405-433 (Volume publication date February 1978)https://doi.org/10.1146/annurev.ps.29.020178.002201
57. Margaret T. Singer & Lyman C. Wynne (1966) Principles for Scoring Communication Defects and Deviances in Parents of Schizophrenics:, Psychiatry, 29:3, 260-288, DOI: 10.1080/00332747.1966.11023470
58. C. Christian Beels, Social Support and Schizophrenia, Schizophrenia Bulletin, Volume 7, Issue 1, 1981, Pages 58–72, https://doi.org/10.1093/schbul/7.1.58
59. Stubbe DE. Enhancing Adherence: Using Mobile Health Technology to Improve Self-Management for Individuals With Schizophrenia. Focus (Am Psychiatr Publ). 2020 Oct;18(4):424-427. Doi: 10.1176/appi.focus.20200028. Epub 2020 Nov 5. PMID: 33343253; PMCID: PMC7725159.
60. Xia J, Merinder LB, Belgamwar MR. Psychoeducation for schizophrenia. Cochrane Database Syst Rev. 2011 Jun 15;2011(6):CD002831. Doi: 10.1002/14651858.CD002831.pub2. PMID: 21678337; PMCID: PMC4170907.
61. Goff DC, Hill M, Freudenreich O. Strategies for improving treatment adherence in schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2010;71 Suppl 2:20-6. Doi: 10.4088/JCP.9096su1cc.04. PMID: 21190649.
62. Holubova M, Prasko J, Hruby R, Kamaradova D, Ociskova M, Latalova K, Grambal A. Coping strategies and quality of life in schizophrenia: cross-sectional study. Neuropsychiatr Dis Treat. 2015 Dec 10;11:3041-8. Doi: 10.2147/NDT.S96559. PMID: 26677331; PMCID: PMC4677764.
63. Jensen-Doss A, Haimes EMB, Smith AM, Lyon AR, Lewis CC, Stanick CF, Hawley KM. Monitoring Treatment Progress and Providing Feedback is Viewed Favorably but Rarely Used in Practice. Adm Policy Ment Health. 2018 Jan;45(1):48-61. Doi: 10.1007/s10488-016-0763-0. PMID: 27631610; PMCID: PMC5495625.
64. Young AS, Niv N, Chinman M, Dixon L, Eisen SV, Fischer EP, Smith J, Valenstein M, Marder SR, Owen RR. Routine outcomes monitoring to support improving care for schizophrenia: report from the VA Mental Health QUERI. Community Ment Health J. 2011 Apr;47(2):123-35. Doi: 10.1007/s10597-010-9328-y. Epub 2010 Jul 25. PMID: 20658320; PMCID: PMC3058510.
65. Gilbody SM, House AO, Sheldon TA. Outcome measures and needs assessment tools for schizophrenia and related disorders. Cochrane Database Syst Rev. 2003;2003(1):CD003081. Doi: 10.1002/14651858.CD003081. PMID: 12535453; PMCID: PMC7017098.

66. Huddy VC, Hodgson TL, Ron MA, Barnes TR, Joyce EM. Abnormal negative feedback processing in first episode schizophrenia: evidence from an oculomotor rule switching task. Psychol Med. 2011 Sep;41(9):1805-14. Doi: 10.1017/S0033291710002527. Epub 2011 Jan 7. PMID: 21211097; PMCID: PMC3154653.
67.Atkinson JR. The perceptual characteristics of voice-hallucinations in deaf people: insights into the nature of subvocal thought and sensory feedback loops. Schizophr Bull. 2006 Oct;32(4):701-8. Doi: 10.1093/schbul/sbj063. Epub 2006 Mar 1. PMID: 16510696; PMCID: PMC2632268.
68.Hans D. Brenner, Bettina Hodel, Volker Roder, Patrick Corrigan, Treatment of Cognitive Dysfunctions and Behavioral Deficits in Schizophrenia, Schizophrenia Bulletin, Volume 18, Issue 1, 1992, Pages 21–26, https://doi.org/10.1093/schbul/18.1.21
69. Delahunty A, Morice R, Frost B. Specific cognitive flexibility rehabilitation in schizophrenia. Psychol Med. 1993 Feb;23(1):221-7. Doi: 10.1017/s0033291700039015. PMID: 8097331.
70. Andreasen NC, Carpenter WT Jr, Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry. 2005 Mar;162(3):441-9. Doi: 10.1176/appi.ajp.162.3.441. PMID: 15741458.
71 .Solmi M, Murru A, Pacchiarotti I, Undurraga J, Veronese N, Fornaro M, Stubbs B, Monaco F, Vieta E, Seeman MV, Correll CU, Carvalho AF. Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. Ther Clin Risk Manag. 2017 Jun 29;13:757-777. Doi: 10.2147/TCRM.S117321. PMID: 28721057; PMCID: PMC5499790.
72. Mccabe R, Saidi M, Priebe S. Patient-reported outcomes in schizophrenia. Br J Psychiatry Suppl. 2007 Aug;50:s21-8. Doi: 10.1192/bjp.191.50.s21. PMID: 18019040.
73. Anja Searle, Luke Allen, Millie Lowther, Jack Cotter, Jennifer H. Barnett,Measuring functional outcomes in schizophrenia in an increasingly digital world,Schizophrenia Research: Cognition,Volume 29,2022,100248,ISSN 2215-0013,https://doi.org/10.1016/j.scog.2022.100248.
(https://www.sciencedirect.com/science/article/pii/S2215001322000130)
74. Olsson AK, Hjärthag F, Helldin L. Predicting real-world functional milestones in schizophrenia. Psychiatry Res. 2016 Aug 30;242:1-6. Doi: 10.1016/j.psychres.2016.05.015. Epub 2016 May 18. PMID: 27235985.
75.Chen TT, Chueh KH, Chen KC, Chou CL, Yang JJ. The Satisfaction With Care of Patients With Schizophrenia in Taiwan: A Cross-Sectional Survey of Patient-Centered Care Domains. J Nurs Res. 2023 Apr 1;31(2):e268. Doi: 10.1097/jnr.0000000000000549. PMID 36976539.